Raltegravir potassium salt

Research use only, not for human use.

A potent, selective, orally bioavailable HIV-integrase inhibitor with IC50 of 15 nM.

A potent, selective, orally bioavailable HIV-integrase inhibitor with IC50 of 15 nM; essentially inactive (IC50s>50 uM) against HCV Pol, HIV RT, HIV RNase-H, and human α/β/γ Pol; shows inhibitory activity against the wild type virus and a selection of mutants; the first HIV-integrase inhibitor for the treatment of HIV-1 infection.HIV Infection Approved

MK0518 potassium salt;MK-0518 potassium salt;MK 0518 potassium salt

Microbiology/Virology

HIV

HIV;Integrase(IN)

Infection

HIV Infection

871038-72-1

482.51

C20H20FKN6O5

>98% (HPLC)

10 mM in DMSO

CC1=NN=C(O1)C(=O)NC(C)(C)C2=NC(=C(C(=O)N2C)[O-])C(=O)NCC3=CC=C(C=C3)F.[K+]

4-Pyrimidinecarboxamide, N-[(4-fluorophenyl)methyl]-1,6-dihydro-5-hydroxy-1-methyl-2-[1-methyl-1-[[(5-methyl-1,3,4-oxadiazol-2-yl)carbonyl]amino]ethyl]-6-oxo-, potassium salt(1:1)

(-20℃)

With Ice Pack

≥ 2 years